Author: Biocytogen Boston

Free Trial of Humanized Animal Models – 5 Free Humanized KnockIn Mice Offer!

September 4, 2023

This promotion has ended, please check out our Humanized Animal Models and Cell lines instead. New Year. New Research Opportunities.   Our Therapeutic Focus Biocytogen’s Preclinical Services Division has established comprehensive in vivo and in vitro pharmacology capabilities and provides world-class services to our customers. Our team has significant expertise in testing novel therapeutics for immuno-oncology, […]

Read More

Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services (BioMice) From Antibody Drug R&D

August 30, 2023

Beijing, China, August 31, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces the official formation of two major business divisions to represent the company’s product, service, and asset portfolio. Over the last decade, Biocytogen has developed several technology platforms to streamline the entire drug development process, including generation of specialized (humanized) […]

Read More

Eucure and Syncromune Establish Technology Transfer Agreement for YH002 (OX40 Antibody) and Multiple Other Clinical-Stage Antibodies

August 30, 2023

BEIJING, China, August 30, 2023 – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today that the company has entered into a technology transfer agreement with Syncromune, Inc. (“Syncromune”), a US-based clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a platform technology designed to […]

Read More

Meet Us at Our Booth in JCA2023!

August 24, 2023

Biocytogen’s Asia-Pacific business development team is pleased to exhibit at the 82nd annual meeting of the Japanese cancer association, taking place from September 21–23, 2023 in Yokohama, Japan! Join us at Booth #42 to learn more about how BioMice® models and services, our fully human antibody discovery platforms and antibody assets can accelerate your R&D […]

Read More

Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth

August 17, 2023

BEIJING, China–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth. Project Integrum is a large-scale R&D project designed to discover novel therapeutic antibodies for more than 1000 druggable targets. The project, which […]

Read More

Biocytogen Announces Grand Opening of Waltham, MA Facility

August 16, 2023

State-of-the-Art Facility Signifies Growth of Business in North America and Europe August 16, 2023, Waltham, MA & Beijing, China – Biocytogen Pharmaceuticals (HKEX: 02315; “Biocytogen”), a biotechnology company focused on the generation and validation of novel antibody-based therapeutics and specialized animal models for partners worldwide, today announces the grand opening of a new 37,000 sqft. […]

Read More

Webinar: Overcoming Difficulties In GPCR Antibody Discovery Using Biocytogen’s Renmice-Based Platform

August 4, 2023

Our webinar “Overcoming Difficulties In GPCR Antibody Discovery Using Biocytogen’s Renmice-Based Platform” was live at 11:00 AM EDT on Aug 30th, 2023.  About the Webinar GPCRs (G protein-coupled receptor) are the most abundant membrane protein in the human genome, and are targeted by approximately one-third of drugs on the market. However, the difficulty in antigen preparation […]

Read More

Join us at the 11th Annual Immuno-Oncology Summit: Aug 7-9

Date: Aug 7-9
Location: Boston

Join us at the 11th Annual Immuno-Oncology Summit from August 7-9 in Boston! Learn more about our in vivo efficacy, PK/PD, toxicity, and in vitro pharmacology platforms.  Attend the meeting Talk to us at the booth! CHI’s IO Summit provides access to a comprehensive 3-day program for participants to evaluate bi- or multi-specific biotherapeutics, explore […]

Read More

Meet us at BIO Asia-Taiwan!

July 19, 2023

Biocytogen’s Asia-Pacific business development team is pleased to host online 1-on-1 meetings at BIO Asia-Taiwan, taking place from July 25-26, 2023! Chat with our team to learn more about our animal models, preclinical services and antibody assets in discovery. Schedule a Meeting with Us BioMice: Innovative Models to Empower Health Sciences BioMice is a sub-brand […]

Read More

Back to top
WordPress Double Opt-in by Forge12